Compositions and methods for the treatment of human immunodeficiency virus
OwnerLaura LILE, Albert CRUMinventors
Life of this patent
Estimating the term…
Abstract
Compositions and methods for inhibiting human immunodeficiency viral infection and for treating subjects already infected with a human immunodeficiency virus such as HIV-1. The compositions and methods reduce HIV viral load in subjects infected with HIV.
Claims19
A method for reducing viral load in a subject infected with a human immunodeficiency virus, the method comprising administering to the subject, on a daily basis and for at least three consecutive days, either one of the following:
- about 2,355 mg glycine, about 2,355 mg L-glutamine, about 1,200 mg L-cystine, about 12 mg coenzyme Q10, and about 0.034 mg selenomethionine;
- or
- about 1,177 mg glycine, about 1,177 mg L-glutamine, about 600 mg L-cystine, about 6 mg coenzyme Q10, and about 0.017 mg selenomethionine.
(canceled)
(canceled)
(canceled)
A method of preventing a human immunodeficiency virus infection in a subject, the method comprising orally administering to the subject a composition either one of the following:
- about 2,355 mg glycine, about 2,355 mg L-glutamine, about 1,200 mg L-cystine, about 12 mg coenzyme Q10, and about 0.034 mg selenomethionine;
- or
- about 1,177 mg glycine, about 1,177 mg 1a-glutamine, about 600 mg L-cystine, about 6 mg coenzyme Q10, and about 0.017 mg selenomethionine.
Use of glycine, L-glutamine, L-cystine, coenzyme Q10, and selenomethionine in the preparation of a medicament for treating HIV-1 infection in a subject.
(canceled)
Dependencies are inferred from the claim text.